Alpha Therapy

Alpha Therapy

 

various methods of therapeutic influence on an organism, primarily by alpha particles. Several short-lived isotopes or those that separate quickly from the organism (radon, daughter products of thoron, and others) are used in alpha therapy. These isotopes produce alpha, beta, and gamma radiation; however, during therapy the organism mainly absorbs alpha particles (about 90 percent). The therapy is administered through radon baths (general and local), drinking of radon water, microsyringe, irrigations, inhalation of air enriched with radon, and so on, as well as by application to certain areas of the patient’s skin of radioactive bandages—gauze applicators with daughter products of thoron—or ointments and solutions with thorium X. Alpha therapy favorably affects the functional state of the central and autonomic nervous system, the endocrine glands, and the cardiovascular system; the therapy has a calming, pain-killing, and anti-inflammatory effect and the like. It is indicated for illnesses of the peripheral nervous system, phantom pains, neurasthenia, thyrotoxicosis (in the early stage), and other conditions. It is contraindicated for malignant tumors, tuberculosis, certain blood diseases, during pregnancy, and the like.

Alpha therapy is used at resorts with natural radon factors (water, air), like Piatigorsk, Tskhaltubo, Belokurikha, Brambach (German Democratic Republic), Gastein (Austria), and Jachymov (Czechoslovakia), as well as under nonresort conditions, in which case radon water is prepared using solutions of radium 220/86.

E. S. SHCHEPOT’EVA

References in periodicals archive ?
Alpha emitters are currently used in the process of Targeted Alpha Therapy (TAT), where in an alpha emitter radionuclide exposes a certain amount of radiation dose to tumor cells, at a very early stage or in the state of metastasis, and destroy the respective cancer cells.
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.
factor (anti-TNF) alpha therapy for chronic inflammatory disorders, and
Horsham, PA) and Schering-Plough Corporation (Kenilworth, NJ) have revised their 1998 distribution agreement regarding the development, commercialization and distribution of both REMICADE (infliximab), an anti-tumor necrosis factor (anti-TNF) alpha therapy for chronic inflammatory disorders, and golimumab, Centocor's next-generation, human, anti-TNF alpha therapy, which is currently in Phase 3 trials.
Sero-conversion against HBV and surface antigen elimination has been reported to be improved by one-to-two years of interferon alpha therapy.
announced today that it entered into an agreement with the Targeted Alpha Therapy Group (TAT Group) at the University of Gothenburg in Sweden to collaborate on the research and development of farletuzumab as an alpha therapy vector being studied for radioimmunotherapy in ovarian cancer.
and Schering-Plough Corporation (NYSE: SGP) today announced they have revised their 1998 distribution agreement regarding the development, commercialization and distribution of both REMICADE(R) (infliximab), an anti-tumor necrosis factor (anti-TNF) alpha therapy for chronic inflammatory disorders, and golimumab, Centocor's next-generation, human, anti-TNF alpha therapy, which is currently in Phase 3 trials.
Interferon alpha therapy in patients with chronic hepatitis C and persistently normal amino-transferase activity.
Targeted alpha therapy is one of the most promising treatments for cancer, which is being researched upon by cancer institutes.
Drivers Major drivers contributing to growth of the market are increasing incidences of cardiac & cancer ailments, increased awareness about the potential benefits of targeted alpha therapy and increasing availability of radiopharmaceuticals.
Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.